Citi raised the firm’s price target on Alnylam (ALNY) to $404 from $364 and keeps a Buy rating on the shares. The firm updated commercial stage biotechnology targets into the Q2 reports.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALNY:
- Alnylam Pharma’s Promising Growth and Market Potential Justify Buy Rating
- Alnylam price target raised to $384 from $328 at Jefferies
- Alnylam announces reimbursement of OXLUMO in Canada
- Strong Sales Momentum and Growth Potential Drive Buy Rating for Alnylam Pharma’s Amvuttra
- Alnylam’s NeuroFeeL Study: A New Frontier in Amyloidosis Biomarker Research